Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension
- 1 February 2015
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 62 (2) , 325-331
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- FXR Agonist INT-747 Upregulates DDAH Expression and Enhances Insulin Sensitivity in High-Salt Fed Dahl RatsPLOS ONE, 2013
- FXR ligands protect against hepatocellular inflammation via SOCS3 inductionCellular Signalling, 2012
- Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressureJournal of Cellular and Molecular Medicine, 2012
- Angiotensin II and NADPH Oxidase Increase ADMA in Vascular Smooth Muscle CellsHypertension, 2010
- Role of Dimethylarginine Dimethylaminohydrolases in the Regulation of Endothelial Nitric Oxide ProductionJournal of Biological Chemistry, 2009
- Vascular biology and pathobiology of the liver: Report of a single-topic symposiumHepatology, 2008
- Hydrodynamic Gene Delivery: Its Principles and ApplicationsMolecular Therapy, 2007
- Endotoxemia produces coma and brain swelling in bile duct ligated ratsHepatology, 2007
- Radixin Is Required to Maintain Apical Canalicular Membrane Structure and Function in Rat HepatocytesGastroenterology, 2006
- Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosisJournal of Hepatology, 2004